Gene
SRSF2
SRSF2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (12), Actionable biomarkers (1), Trial mentions (31), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SRSF2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 3 of 8,738 | 0.03% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 5 of 8,597 | 0.06% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 20 of 11,460 | 0.17% |
| 2022 | 2 of 8,285 | 0.02% | 17 of 13,598 | 0.13% |
| 2021 | 5 of 8,692 | 0.06% | 25 of 15,045 | 0.17% |
| 2020 | 2 of 7,640 | 0.03% | 11 of 14,459 | 0.08% |
| 2019 | 1 of 7,300 | 0.01% | 9 of 12,159 | 0.07% |
| 2018 | 4 of 6,927 | 0.06% | 21 of 11,854 | 0.18% |
| 2017 | 1 of 6,558 | 0.02% | 11 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (12)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BC-BIO | Reagent supplier | Clinical validation | 1 | December 21, 2020 |
| CDI Laboratories | Reagent supplier | Clinical validationAnalytical validation | 2 | December 21, 2020 +1 undated |
| CLOUD CLONE CORP | Reagent supplier | Clinical validation | 1 | December 21, 2020 |
| CUSABIO | Reagent supplier | Clinical validation | 1 | December 21, 2020 |
| Agilent Technologies | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | November 01, 2020 |
Showing 5 of 12 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SRSF2 oncogenic mutation | Spliceosome Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
Trial mentions (31)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT03427866 | Trial eligibility (AACT) |
| NCT04526288 | Trial eligibility (AACT) |
| NCT06152809 | Trial eligibility (AACT) |
| NCT06297629 | Trial eligibility (AACT) |
Showing 5 of 31 trial mentions.
Target-disease associations (269)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Abnormality of metabolism/homeostasis | phenotype | gene burden |
| Absence of circulating granulocytes | phenotype | gene burden |
| Absence of circulating granulocytes | phenotype | GWAS credible sets |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 269 associations.
Vendor sourcing (105)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.530C>G (p.S177C) alteration is located in exon 2 (coding exon 2) of the SRSF2 gene. This alteration results from a C to G substitution at nucleotide po... | View ClinVar record SCV003636678.2 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Biospecimen collected in a trialTrial biospecimen collection | No supporting text recorded; see the citation. | View trial NCT02823210 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Mentioned in trial textTrial free-text mention | SRSF2 | View trial NCT02823210 |
| Astex Pharmaceuticals | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Diagnosis of AML and MDS according to World Health Organization (WHO) classification that underwent first or second allogeneic HSCT with either peripher... | View trial NCT06297629 |
| Astex Pharmaceuticals | Trial collaborator | Mentioned in trial textTrial free-text mention | SRSF2 | View trial NCT06297629 |
Showing 5 of 105 sourcing records.
Trial-cited literature (170)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies. | Scientific reports | 2025 | 5 |
| Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. | Therapeutic advances in hematology | 2025 | 2 |
| Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). | Leukemia | 2024 | 35 |
Showing 5 of 170 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A171V | 1 | 2017 | PMID 28516000 |
| p.A278T | 1 | 2017 | PMID 28475860 |
Literature-extracted relations (64)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CISPLATIN | Chemical | positive_correlate |
Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. | 2011 |
| Myelodysplastic Syndromes | Disease | associate |
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. | 2023 |
| Myelodysplastic Syndromes | Disease | associate |
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. | 2023 |
| Neoplasms | Disease | associate |
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. | 2022 |
| Cardiovascular Diseases | Disease | associate |
Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. | 2021 |
Showing 5 of 64 relation assertions.
Organizations publishing (236)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 19 | 2015 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 17 | 2015 to 2023 |
| Mayo Clinic | Hospital | 14 | 2013 to 2022 |
| University of Florence | Academic | 13 | 2013 to 2026 |
| The University of Texas System | Academic | 12 | 2013 to 2026 |
Showing 5 of 236 organizations.
Where SRSF2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- medical procedure
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
226 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.